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Summary
Objective: This study was designed to test the utility of a blood-based approach to identify mild osteoarthritis (OA) of the knee.
Methods: Blood samples were drawn from 161 subjects, including 85 subjects with arthroscopically diagnosed mild OA of the knee and 76
controls. Following RNA isolation, an in-house custom cDNA microarray was used to screen for differentially expressed genes. A subset of
selected genes was then tested using real-time RT-PCR. Logistic regression analysis was used to evaluate linear combinations of the
biomarkers and receiver operating characteristic curve analysis was used to assess the discriminatory power of the combinations.
Results: Genes differentially expressed (3543 genes) between mild knee OA and control samples were identiﬁed through microarray analysis.
Subsequent real-time RT-PCR veriﬁcation identiﬁed six genes signiﬁcantly down-regulated in mild OA: heat shock 90 kDa protein 1, alpha;
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein; interleukin 13 receptor, alpha 1; laminin,
gamma 1; platelet factor 4 (also known as chemokine (C-X-C motif) ligand 4) and tumor necrosis factor, alpha-induced protein 6. Logistic
regression analysis identiﬁed linear combinations of nine genes e the above six genes, early growth response 1; alpha glucosidase II alpha
subunit; and v-maf musculoaponeurotic ﬁbrosarcoma oncogene homolog B (avian) e as discriminatory between subjects with mild OA and
controls, with a sensitivity of 86% and speciﬁcity of 83% in a training set of 78 samples. The optimal biomarker combinations were then
evaluated using a blind test set (67 subjects) which showed 72% sensitivity and 66% speciﬁcity.
Conclusions: Linear combinations of blood RNA biomarkers offer a substantial improvement over currently available diagnostic tools for mild
OA. Blood-derived RNA biomarkers may be of signiﬁcant clinical value for the diagnosis of early, asymptomatic OA of the knee.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Abbreviations: AD1f2, a reference data set of DCt values, from RT-PCR analysis of 36 controls and 42 mild osteoarthritis peripheral blood
samples, AD1k, a composite of AD1f2 of 78 samples and the 67 blind samples, BMI, body mass index, EGR1, early growth response 1, F,
female, G2AN, alpha glucosidase II alpha subunit, HSPCA, heat shock 90 kDa protein 1, alpha, IKBKAP, inhibitor of kappa light polypeptide
gene enhancer in B-cells, kinase complex-associated protein, IL13RA1, interleukin 13 receptor, alpha 1, KL, KellgreneLawrence, LAMC1,
laminin, gamma 1, M, male, MAFB, v-maf musculoaponeurotic ﬁbrosarcoma oncogene homolog B (avian), OA, osteoarthritis, PF4, platelet
factor 4 (also known as chemokine (C-X-C motif) ligand 4), ROC, receiver operating characteristic, TNFAIP6, tumor necrosis factor, alpha-
induced protein 6, TNF, true negative fraction, TPF, true positive fraction.
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Blood is considered as an ideal surrogate for disease
diagnosis because it is readily available and can be
obtained relatively non-invasively. Blood interacts and
communicates with every tissue and organ in the body.
Blood is also a notably highly dynamic tissue. It involves
a daily turnover of 200 billion red blood cells and 70 billion
neutrophilic leukocytes a day1. In view of the dynamic and
interactive properties of circulating blood, blood cells may
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Received 11 May 2005; revision accepted 5 June 2005.86function as ‘‘sentinels’’ which can reﬂect the status of the
current state of health or disease throughout the body2. Our
hypothesis is that blood-derived RNA expression can
provide an alternative to tissue biopsy and imaging for the
diagnosis and prognosis of disease. We are applying this
Sentinel Principle to identify biomarkers useful to diagnose
disease.
The ability to utilize blood-derived RNA expression for
disease diagnosis was ﬁrst demonstrated in the study by
Ma and Liew3. This study successfully identiﬁed differen-
tially expressed genes in the blood from healthy control
subjects and from coronary artery disease patients3. A
number of subsequent studies have also independently
explored and veriﬁed the use of blood-derived RNA
expression to diagnose disease in a broad range of1
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the long-term effects of renal transplantation6. Neuropath-
ological conditions were also detectable by this ap-
proach7,8, an important consideration since the brain is
isolated from the peripheral circulation by the bloodebrain
barrier. This was further underscored by a recent study on
psychiatric disorders, in which eight genes expressed in the
cells of the peripheral blood were able to discriminate
between patients with schizophrenia or bipolar disorder and
healthy controls9.
In this study, we investigate the possible utility of using
a blood-based approach for diagnosing subjects with mild
osteoarthritis (OA) of the knee. Although articular cartilage
is considered avascular, and OA is usually considered
a local disease, recent insights of OA suggest that system
biology plays a critical part in OA aetiology and pathophys-
iological processes10. Furthermore, evidence that the
Sentinel Principle can be effectively applied to central
nervous disorders where there is a bloodebrain barrier9
suggests that this approach could also be efﬁcacious for
early (mild) OA where there is a bloodesynovial ﬂuid barrier.
The need for a diagnostic tool for early OA is pressing.
Currently, diagnosis of OA is mainly based on symptoms
such as joint pain and changes observed radiologically
(e.g., KellgreneLawrence (KL) scoring system). However,
these approaches are currently effective only in detecting
intermediate or late-stage OA. Early diagnosis remains
a challenge: the progression of cartilage damage and
degradation is typically slow and extensive joint degener-
ation may have occurred before clinical signs and symp-
toms become apparent11,12. It has been suggested that
serum and or urine levels of degraded or newly synthesized
fragments of cartilage matrix components (e.g., collagen
type II c-telopeptides, collagen type II propeptides and
aggrecan)10,13 might serve as potential biomarkers for early
cartilage damage, but the utility of this approach for
diagnosis has not been fully established. There currently
are no validated biomarkers for identifying early OA.
In this study, we collected and analyzed a total of 161
peripheral blood samples, including 85 subjects with early
OA of the knee and 76 controls. We proﬁled a total of 68
subjects (29 controls and 39 mild knee OA patients) in
two sets of experiments using a custom cDNA microarray
to identify differentially expressed genes. A subset of
genes was assessed by real-time RT-PCR. Logistic
regression was used to generate linear combinations of
biomarkers. Linear combinations of nine of the genes
[early growth response 1 (EGR1), alpha glucosidase II
alpha subunit (G2AN), heat shock 90 kDa protein 1, alpha
(HSPCA), inhibitor of kappa light polypeptide gene
enhancer in B-cells, kinase complex-associated protein
(IKBKAP), interleukin 13 receptor, alpha 1 (IL13RA1),
laminin, gamma 1 (LAMC1), v-maf musculoaponeurotic
ﬁbrosarcoma oncogene homolog B (avian) (MAFB),
platelet factor 4 (also known as chemokine (C-X-C motif)
ligand 4) (PF4), tumor necrosis factor, alpha-induced
protein 6 (TNFAIP6)] tested yielded receiver operating
characteristic (ROC) curve areas of R0.90 for a reference
set of 78 samples (52 samples used in microarray and 26
additional samples). Of the 78 samples, 42 subjects had
mild knee OA and 36 were controls. Furthermore, we
evaluated these biomarker combinations against a blind
set of an additional 67 samples (32 mild knee OA and 35
controls) which resulted in a sensitivity of 72% and
a speciﬁcity of 66%. Our studies indicate that some
biomarker combinations might have clinical utility for
detecting mild OA of the knee.Methods
RECRUITMENT OF CONTROLS AND OA PATIENTS
Patientswere recruited from theTorontoWesternHospital,
University Health Network (UHN), at the University of
Toronto. The UHN Research Ethics Board approved the
research and participants provided written informed consent.
Patients were diagnosed with mild OA adventitiously, while
undergoing arthroscopy as a consequence of meniscal
tearing, anterior cruciate ligament (ACL) injury and/or patellar
maltracking. Severity was graded with an established
arthroscopic scoring method14. Brieﬂy, this system assigns
a score of 0e4 to the worst lesion on each of six articular
surfaces.Grade0 is normal (0 points),Grade I cartilage is soft
or swollen but the articular surface is intact (1 point). In Grade
II lesions, the cartilage surface is not intact but the lesion does
not extend down to subchondral bone (2 points). Grade III
damage extends to subchondral bone but the bone is neither
eroded nor eburnated (3 points). In Grade IV lesions, there is
eburnation of, or erosion into, bone (4 points). The score from
all surfaces is summed to produce a global score, which is
used to categorize OA severity as mild (early): 1e6;
moderate: 7e12; marked: 13e18; and severe: 19e24. For
this study, we included only patients whose global score was
1e6 (mild); we speciﬁcally excluded any patients with
traumatic chondral lesions, rheumatoid arthritis, infectious
arthritis or psoriatic arthritis. Themild OA group had changes
reﬂecting the earliest changes of OA including diffuse
cartilage softening and superﬁcial ﬁbrillation across multiple
articular surfaces. Control subjects who had no knee
symptoms and no history of previous knee injury were
recruited for the study. Detailed patient information is
provided in supplement Table 1.
BLOOD RNA ISOLATION
Peripheral whole blood (10 ml) was collected in Vacutainer
tubes containing ethylenediaminetetraacetic acid (EDTA)
(BectonDickinson, Franklin Lakes,NJ) and stored on ice until
processing (within 6 h). Upon centrifugation, blood samples
separated into plasma, buffy coat and red blood cell layers.
The plasma was removed and a hypotonic buffer (1.6 mM
EDTA, 10 mMKHCO3, 153 mMNH4Cl, pH 7.4) was added to
lyse the red blood cells at a 3:1 volume ratio. Themixture was
centrifuged to yield a cell pellet, which was dissolved and
homogenized into 1.0 ml of TRIzol Reagent (Invitrogen
Corp., Carlsbad, CA) and 0.2 ml of chloroform according to
the manufacture’s instructions. After centrifugation, isopro-
panol was added to the aqueous phase at a 1:1 ratio and
allowed to precipitate at 20(C. Subsequent centrifugation
yielded an RNA pellet that was resuspended in water for
experimental use. RNA quality was assessed on Agilent
2100 Bioanalyzer RNA 6000 Nano Chips as speciﬁed by the
manufacturer, and RNA quantity was determined by absor-
bance at 260 nm in a Beckman-Coulter DU640 Spectropho-
tometer.
MICROARRAY HYBRIDIZATION
A custom cDNA microarray was constructed using clones
derived from our in-house cDNA clone bank that provides
comprehensive coverage of the estimated 13e16,000
genes that are expressed by chondrocytes15e17. The array
contains 14,976 distinct elements: w69% were known
genes, w27% were expressed sequence tags (EST)/
genomic DNA matches, w3.5% of the spots were clones
with no signiﬁcant match, and w0.8% of the spots were
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Primers used for real-time RT-PCR
Symbol Ref. ID 5# Primer 3# Primer Product
Primer sequence Position Primer sequence Position
EGR1 NM_001964 GACCGCAGAGTCTTTTCCTG 570 CACAAGGTGTTGCCACTGTT 719 150
G2AN NM_014610 TTCCTGCTGCGTCGATTCTCA 2667 TTATCACCACCCGCTCAATCCA 2772 106
HSPCA NM_005348 ATGATTGGCCAGTTCGGTGTTG 448 TTCACCTGTGTCTGTCCTCACT 594 147
IKBKAP NM_003640 GCAGCCCAGCTTAACTTTACCA 3411 TAATCCTGGGCACACTCTTCCA 3535 125
IL13RA1 NM_001560 CATTGTTCCAGTCATCGTCGCA 1093 TCTTGCCAGGATCAGGAATTGG 1193 101
LAMC1 NM_002293 CAGGCTCCATGAAGCAACAGA 2174 GCACTTCTCTCACTGTATGTCCCAC 2293 120
MAFB AF134157 CCCTTGTTTCTTTGGGTGAG 1786 ACGTTCTCTATGCGGTTTGG 1904 119
PF4 NM_002619 GTTGCTGCTCCTGCCACTT 61 GTGGCTATCAGTTGGGCAGT 231 171
TNFAIP6 NM_007115 ATATGGCTTGAACGAGCAGC 161 TGGCCGCCTTCAAATTCACA 267 107control spots. During the course of this study, two sets of
cDNA arrays were used. Information on genes in each set
array is given in supplement Table 2.
Microarray hybridization was carried out as described
previously15 with minor modiﬁcations. In brief, RNA
samples were reverse transcribed to cDNA, labeled with
Cy5-dUTP ﬂuorescent dye (Amersham Biosciences, Piscat-
away, NJ), and applied to the microarray slides (37(C
overnight). Cy3-labelled Universal Human Reference RNA
(Stratagene, La Jolla, CA) was employed as the reference
hybridization control in all experiments.
Two sets of microarray experiments (Set 1 and Set 2)
were performed:
Set 1 Fourteen samples e six controls (3F/3M; mean
age: 41 years, age range: 32e47 years; mean
body mass index (BMI): 24.9, range: 22.1e27.2)
and eight mild OA patients (3F/5M; mean age: 30
years, age range: 21e44 years; mean BMI: 24.8;
range: 20.9e30.3).
Set 2 Fifty-seven samplese 25 controls (13F/12M; mean
age: 35 years, age range: 23e51 years; mean BMI:
25.0, range:18.0e40.0) and 32 mild OA patients
(14F/18M; mean age: 33 years, age range: 22e52
years; mean BMI: 26.6, range:19.2e34.9). Two
control samples and one mild OA sample were the
same as used in Set 1.
MICROARRAY DATA ANALYSIS
Images of Cy3 and Cy5 ﬂuorescence were generated
with a GMS 428 Array Scanner (Affymetrix, Santa Clara,CA) and processed using the software ScanAlyze v2.44
(Michael Eisen, Berkeley, CA), to quantitate target signal
intensities. Lowess normalization was performed to remove
dye bias, and unreliable low-intensity genes were removed
prior to further analysis (GeneSpring v6.0, Silicon Genetics,
Redwood City, CA). Genes were ﬁltered so that only genes
with a signal/background ratio R 1.5 across the whole set
were selected for further analysis. Differentially expressed
genes were identiﬁed by (1) pair-wise (Wilcoxone
ManneWhitney) non-parametric, (2) parametric (Welch t
tests (P! 0.05)), and (3) un-supervised analysis. In the un-
supervised analysis, the signal-intensity ﬁltered genes were
used to select genes with at least 1.5-fold change (up or
down) in level of expression from the mean in at least 20%
of the samples18. Gene-speciﬁc biases introduced by
differences in scanner settings, microarray slide batch,
hybridization date, patient age or BMI were detected by
non-parametric statistical tests (P! 0.05), and the affected
genes were removed prior to subsequent analysis. Results
were visualized with agglomerative hierarchical cluster
analysis using Spearman correlation as the similarity
measure with average centroid linkage in GeneSpring v6.0.
REAL-TIME RT-PCR
We designed forward and reverse primers using ‘‘Primer-
Quest’’ (http://biotools.idtdna.com/primerquest, Integrated
DNA Technologies, Coralville, IA) for the following genes:
EGR1, G2AN, HSPCA, IKBKAP, IL13RA1, LAMC1, MAFB,
PF4 and TNFAIP6 (or TSG-6). The primer sets for the nine
genes are given in Table I. Serial dilution measurements for
target gene and housekeeping gene beta-actin (ACTB)
were used to ensure that the values were within linearTable II
Information on patients used for RT-PCR. The samples used in AD1f2 did not overlap with patients used in blind test. Parameters including
sample size, gender, age, BMI OA score and KL score of the knee are listed. NAZ not available. *one sample missing BMI information
AD1f2 Blind test
Control Mild OA Control Mild OA
Sample size 36 42 35 32
Gender (F/M) 17/19 18/24 11/24 12/20
Age mean (range) 33 (22e51) 31 (21e52) 41 (20e67) 33 (20e65)
BMI mean (range) 25 (18e40)* 26 (19e35) 24 (16e31) 26 (19e37)
OA score mean (range) 4 (2e6) 4 (2e6)
KL score (no. of patient) 0 (25) 0 (9)
1 (2) 1 (4)
2 (2) 2 (0)
NA (13) NA (19)
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equal for the target and ACTB. ACTB was selected as
housekeeping gene because no statistically signiﬁcant
differences were observed between control and disease
group in this study. An automatically calculated melting
point dissociation curve and agarose gels were used to
examine and ensure the speciﬁc PCR ampliﬁcation and the
lack of primer-dimer formation in each well.
For real-time RT-PCR assays, oligo(dT)-primed ﬁrst
strand cDNA was synthesized with an Applied Biosystems
High Capacity cDNA Archive Kit (cat # 4322171), on
a PerkineElmer DNA Thermal Cycler, according to the
manufacturer’s protocol. Speciﬁc cDNAs were quantitated
by real-time PCR, with the Qiagen Quantitect SYBR
Green PCR Kit (cat # 204143). Amplicons were detected,
using an Opticon I DNA Engine (MJ Research) with
conﬁrmation of speciﬁc ampliﬁcation determined by calcu-
lated melting dissociation curve. Relative fold change of
each individual gene was calculated using the comparative
Ct equation (User Bulletin #2, 2001, Applied Biosystems) as
follows: 2DDCt where DDCtZDCt (of a sample)mean
DCt (of the control samples). DCtZCt (target gene)Ct
(housekeeping gene) where Ct values of target genes were
normalized to housekeeping gene (b-actin).
A reference (training) data set (AD1f2) was constructed
which contained DCt values for the above nine genes
assayed against a total of 78 samples, including 36 controls
(17F/19M, with mean age 33 years ranging from 22 years to
51 years and mean BMI 25 ranging from 18.0 to 40.0 with
one sample missing BMI) and 42 mild knee OA subjects
(18F/24M with mean age of 31 years ranging from 21 years
to 52 years and mean BMI 26.1 ranging from 19.2 to 34.9).
Patient information on AD1f2 including age, gender, BMI,
OA score and KL score is summarized in Table II. Due to
limited quantities of RNA from a few samples, this data
matrix contained four empty data points, which were ﬁlled
with the average DCt values for the genes (the DCt values
of this reference data set AD1f2 are provided in supplement
Table 3).
STATISTICAL ANALYSIS OF REAL-TIME RT-PCR DATA
The statistical signiﬁcance of a difference in mean fold
change between control and mild OA samples for each
gene was evaluated with a ManneWhitney test (SigmaStat,
Table III
Summary of microarray analysis gene lists. Numbers of genes
identified from supervised (WMWZWilcoxoneManneWhitney,
and WTTZWelch t test) and un-supervised analysis on the two
sets of experiments (Set 1 and Set 2) are listed. The number and
the percentage of overlap from different analysis are also listed.
Methods
Supervised
Set WMW WTT Un-supervised
1 1235 1050 1744
Overlap 969 (74%)
257 (9%)
2 632 616 307
Overlap
513 (70%)
96 (10%)
1 & 2 Overlap 10SPSS Inc., Chicago, IL). A P value !0.05 was considered
statistically signiﬁcant.
Pearson correlation (correlation coefﬁcient r) was used as
a measure of the strength of a relationship between two
variables (e.g., age andDCt value). To test the signiﬁcance of
the correlation coefﬁcient, we computed the t value using
formula tZr
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðn 2Þ=ð1 r2Þ
p
, where nZ sample size and
n 2 represents the degrees of freedom (df). For a sample
size of 78, df is 76, tO 1.99 gives a two-tailed signiﬁcance of
P! 0.05, and tO 2.89 gives signiﬁcance of P! 0.005. In
addition, we did a permutation test (usingPerl script)18. In this
test, the order of one variable data set was ﬁrst randomized
and then tested for Pearson correlation coefﬁcient of the two
variable data sets. Permutation was repeated 10,000 times.
In every round of permutation, the r value obtained from the
randomized data was compared to the r value obtained from
the real data. In the end, the number of permutation cycles
with r_realO r_perm was counted and compared to the total
number of permutations. (r_realO r_perm)O 9500 corre-
sponded to a signiﬁcance of P! 0.05.
LOGISTIC REGRESSION
We used logistic regression19e22 to analyze the de-
pendence of the binary diagnostic variable Y (0Z control,
1Z disease) on the DCt values from the reference data set
AD1f2. If PZ probability that a patient sample is diagnosed
as ‘‘diseased’’, then a function XZ Logit(P) can be deﬁned
as follows:
XZLogitðPÞZlnðP=ð1PÞÞZb0Cb1DCt1Cb2DCt2
C.CbnDCtn
ð1Þ
If XO 0 then YZ 1 (diagnosisZ ‘‘diseased’’), and if
X! 0 then YZ 0 (diagnosisZ ‘‘control’’). The (empirical)
coefﬁcients {bi} that deﬁne the relationship between X and
the experimental measurements {DCti} were obtained by
a maximum-likelihood (ML) ﬁtting method. We obtained
identical {bi} values using two different software programs:
MedCalc (MedCalc Software, Mariakerke, Belgium) and XL-
Stat (Addinsoft Software, Paris, France). ROC curve
analysis was then used to evaluate the discriminatory
power of the combinations23e25.
PROSPECTIVE (BLIND) TEST
We conducted a blind test of 67 samples including 35
controls and 32 mild OA subjects (none of the 67 samples
was used in reference data set AD1f2). Patient information
on this blind set including age, gender, BMI, OA score and
KL score is summarized in Table II. Each blind sample was
run on a single 96-well plate for real-time RT-PCR and each
of the nine genes was measured in quadruplicates.
The measured values for each blind sample were
evaluated using the following algorithm, which consists of
an initial calculation, a binary logic gate, and a ‘‘committee
machine’’ vote. Initial Calculation: The logit function Xi is
computed for each of the equations (iZ 1 to N ) that gave
ROC areaO 0.90 against the reference data set AD1f2.
Logic Gate: If Xi! 0, then the blind sample is given score
SiZ1 for Eq. (i). If XiO 0, then it is given score SiZC1
for Eq. (i). Vote by Committee Machine26: A vote is taken
over the scores from the N logit equations used for
diagnosis. By deﬁnition, VoteZ
P
Si. If Vote% 0, then the
sample is called ‘‘control’’, while if VoteO 0 then the sample
is called ‘‘diseased’’.
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Data (DCt values) from the 67 blind samples were
combined with those from the 78 samples in reference data
set AD1f2, to produce a new composite data set, AD1k, with
a total of 145 samples (71 controls and 74 mild OA
samples). The composite data set was then analyzed using
the ‘‘simple logistic regression’’ function in WEKA (http://
www.cs.waikato.ac.nz/ml/weka/), in cross validation mode
with the ‘‘fold’’ parameter set at 145 (the ‘‘leave-one-out’’
setting). In this analysis mode, one sample is removed from
the starting set of 145 samples, logistic regression is
performed on the remaining 144 samples, and the resultant
logit equation is used to predict the state of the removed
sample. The sample is then replaced, to regenerate the
AD1k data set. This process is repeated a total of 145
times, with a different sample removed each time. The
results of the 145 trials are then averaged.
Results
EXPRESSED GENE PROFILES FROM BLOOD CAN
DISTINGUISH MILD OA AND CONTROL
We initially proﬁled gene expression from six control and
eight mild OA patient blood samples as a pilot study (Set 1).
Pair-wise (WilcoxoneManneWhitney) non-parametric stati-
stical analysis identiﬁed a set of 1235 genes with a P! 0.05
that could differentiate controls from mild OA samples.
Although this comparison proved able to separate the
control and mild OA groups, the sample size was limited.
Thus, gene proﬁling was extended to a set of 25 controls and
32 subjects with mild knee OA (Set 2). A set of 632 genes
with a P! 0.05 using pair-wise (WilcoxoneManneWhitney)
non-parametric statistical analysis could distinguish 21 of the
25 controls from 21 of the 32 mild OA patients (Fig. 1).
Parametric Welch t test and un-supervised analysis were
also applied to the two data sets to identify differentially
expressed genes. The number of genes identiﬁed from each
analysis is summarized in Table III. Non-parametric and
parametric analysis gave an overall of 70%overlap of genes.
However, supervised and un-supervised method did not
have much overlap (w10%). The compiled non-redundant
gene list (3543 genes along with their mean intensity,
standard deviation of each group and P values) of the
analysis on the two data sets is provided in supplement
Table 4.
REAL-TIME RT-PCR STUDIES
Candidate genes were selected for real-time RT-PCR
assay based on the following criteria: (1) microarray data
analysis (P value, fold change, number of appearance in
the analysis and relative biological relevance); (2) our
previous OA cartilage EST ﬁndings (normal, mild and
severe OA cartilage cDNA libraries); and (3) the literature.
Nine of the tested genes, namely, EGR1, G2AN, HSPCA,
IKBKAP, IL13RA1, LAMC1, MAFB, PF4 and TNFAIP6,
were identiﬁed as signiﬁcantly different between controls
and mild OA subject with initial testing with smaller sample
size (n! 20/group, data not shown). These genes were
further tested using a set of 78 samples (36 controls and 42
mild OA subjects as a reference data set AD1f2).
When analyzed individually, six of these genes (HSPCA,
IKBKAP, IL13RA1, LAMC1, PF4 and TNFAIP6) showed
signiﬁcant down-regulation in mild OA subjects as com-
pared to controls (Fig. 2). Of the six genes, three of them(HSPCA, TNFAIP6 and IKBKAP) correlated with the
microarray result (all down-regulated in mild OA).
Pearson correlation and permutation test were used to
assess correlations of each of the nine genes with age,
BMI or OA score. The correlation results are shown in
Table IV. HSPCA was signiﬁcantly correlated with OA
score by Pearson correlation test (P! 0.05). LAMC1
showed signiﬁcant correlation with BMI by both Pearson
correlation test (P! 0.005) and Permutation test
(P! 0.05). None of the nine genes was signiﬁcantly
correlated with age.
REFERENCE DATA SET (AD1F2) FOR THE BEST GENE
COMBINATIONS
We used logistic regression to create different combina-
tions of the candidate biomarkers, which were then used to
analyze reference data set AD1f2. Figure 3 presents the top
ﬁve best biomarker combinations with overall ROC areas
greater than 0.92. Their logistic regression parameter
values are highlighted and given in supplement Table 5.
Of the 29 1Z 511 possible biomarker combinations, 68
combinations (see supplement Table 5) were well behaved
in logistic regression and gave signiﬁcant discrimination of
‘‘mild OA’’ vs ‘‘control’’ (ROC areaO 0.90). These 68
combinations were used for subsequent blind sample
predictions.
PREDICTION OF BLIND SAMPLES
A blind test was conducted on an additional set of 67
samples (35 controls, 32 mild OA). The blind test was
designed to diagnose a sample as either ‘‘mild OA’’ or
‘‘control’’. For the set of blind samples the sensitivity (true
positive fraction, TPF) is 72%, and the speciﬁcity (true
negative fraction, TNF) is 66%, with an overall accuracy of
69% (Table V).
CROSS VALIDATION
The composite data set (AD1k, 145 samples) was
analyzed using the ‘‘simple logistic regression’’ function in
WEKA, in cross validationmodewith the ‘‘fold’’ parameter set
at 145 (the ‘‘leave-one-out’’ setting). Initial analysis of
composite data set AD1k: logit equation XZ15.6 0.32*
(G2AN)C 1.01*(HSPCA) 0.22*(IKBKAP)C 1.27*(IL13R
A1)C 0.4*(LAMC1) 1.15*(MAFB)C 1.03*(PF4)C 0.47*
(TNFAIP6), ROC areaZ 0.85, overall accuracyZ 77%,
sensitivity (TPF)Z 78%, speciﬁcity (TNF)Z 77%. Leave-
one-out cross validation: ROC areaZ 0.80, overall
accuracyZ 77%, sensitivity (TPF)Z 76%, speciﬁcity
(TNF)Z 78%.
Discussion
Disease-speciﬁc gene expression signatures in periph-
eral blood have been described for a number of conditions
including coronary artery disease3, schizophrenia and
bipolar disorder9, rheumatoid arthritis, juvenile arthritis,
and spondyloarthropathy27,28. In this study, we have
demonstrated that gene expression signatures from blood
can distinguish between patients with mild OA and controls.
Our results suggest that a combination of biomarkers
obtained from blood may be used as a non-invasive method
to diagnose mild OA of the knee.
866 K. W. Marshall et al.: Blood biomarkers for osteoarthritisFig. 1. Comparison of blood gene expression proﬁles from 25 controls and 32 subjects with mild knee OA. A total of 25 controls and 32 patients
were clustered according to the expression of 632 signiﬁcantly (P! 0.05) differentially expressed genes identiﬁed from a set of 4083 ﬁltered
genes. Samples: control (green), patients (red). The columns indicate gene expression proﬁles for each sample and each row represents the
expression level of a single gene in each of the samples. The color of each row indicates the relative level of gene expression (blue to
redZ low to high in expression).American College of Rheumatology (ACR) criteria state
that for a diagnosis for knee OA the subject must be over the
age of 50, and must be experiencing knee pain in
combination with clinical signs (e.g., stiffness), or X-ray
changes (http://www.rheumatology.org/publications/classiﬁ-
cation/oaknee.asp?audZmem). However, since OA is aninsidious disease with indeterminate onset and slow pro-
gression, ACR criteria tend to identify intermediate or late-
stage OA, and do not identify early OA. Arthroscopy of the
joint could identify early cartilage damage and lesions and
enable a diagnosis of early OA. Patients who present with
meniscal tearing, ACL injury and/or patellar maltracking,Table IV
Correlation analysis of the nine genes with age, BMI and OA score using AD1f2 data set. AD1f2Z 36 controlsC 42 mild OA, dfZ 76 for age
and BMI correlation test, and dfZ 40 for the OA score correlation test. Bold values indicate the statistical significance and italic genes are the
genes with significant correlation
Gene Age BMI OA score
Real_CorrOPerm
(O9500, P! 0.05)
Pearson correlation
r_t (O1.99, P! 0.05)
Real_CorrOPerm
(O9500, P! 0.05)
Pearson correlation
r_t (O2.89, P! 0.005)
Real_CorrOPerm
(O9500, P! 0.05)
Pearson correlation
r_t (O2.02, P! 0.05)
EGR1 143 0.02 2919 0.33 2277 0.35
G2AN 6752 1.20 94 0.01 6587 1.15
HSPCA 8888 1.87 2765 0.26 9367 2.08
IKBKAP 1985 0.39 1520 0.13 9089 1.89
IL13RA1 3553 0.50 998 0.09 542 0.08
LAMC1 6282 1.02 9932 3.24 604 0.09
MAFB 2361 0.38 1571 0.15 420 0.06
PF4 4496 0.68 5260 0.63 5677 0.90
TNFAIP6 1494 0.21 5455 0.59 6830 1.15
867Osteoarthritis and Cartilage Vol. 13, No. 10IKBKAP
IL13RA1 LAMC1
Control Mild OA
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Control Mild OA
0.0
0.5
1.0
1.5
2.0
2.5
Control Mild OA
0.0
0.5
1.0
1.5
2.0
2.5
Control Mild OA
0
1
2
3
4
Control Mild OA
0
1
2
3
4
5
Control Mild OA
0
1
2
3
4
5
P=0.011 P=0.001
P=0.001 P=0.042
P=0.003 P=0.002
HSPCA
PF4 TNFAIP6
Fig. 2. Blood mRNA levels for HSPCA, IKBKAP, IL13RA1, LAMC1, PF4 and TNFAIP6 in control and mild OA patients. Steady-state mRNA
levels were quantitated by two-step SYBR Green real-time RT-PCR. Comparative Ct method was used for the calculation (relative to controls).
Values (meanGSD) between controls (nZ 36) and mild OA (nZ 42) were 1.06G 0.38 and 0.86G 0.30 for HSPCA, 1.08G 0.42 and
0.79G 0.30 for IKBKAP, 1.07G 0.43 and 0.82G 0.38 for IL13RA1, 1.29G 1.02 and 0.71G 0.46 for LAMC1, 1.21G 0.75 and 0.54G 0.34 for
PF4, 1.27G 0.97 and 0.94G 0.78 for TNFAIP6. The lines inside the boxes denote the medians. The boxes mark the interval between the 25th
and 75th percentiles. The whiskers denote the interval between the 10th and 90th percentiles. The ‘‘’’ indicates data points outside the 10th
and 90th percentiles. The plots for EGR1, G2AN and MAFB are not shown as they did not reach statistical signiﬁcance as single biomarkers.often suffer early degenerative cartilage changes in more
than one articular surface. For example, in our reference
data set (AD1f2) of 42 patients with mild OA, ﬁbrillation
changes were observed at the lateral tibial plateau, lateral
femoral chondyle, medial femoral chondyle and medial tibial
plateau of the articular cartilage of the knee. However,arthroscopy is an invasive procedure which limits its utility
as an early diagnostic tool. And that partly results in the
limitation of our deﬁnition of the control group: controls were
not followed by arthroscopic examination to conﬁrm their
status as ‘‘control’’, and some subjects may have had early
asymptomatic cartilage lesion, a subpopulation, which, if it
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Fig. 3. ROC curves for biomarker combinations. This ﬁgure presents the top ﬁve ROC curves for biomarker combinations that successfully
discriminate mild OA from control samples in reference data set AD1f2. AUCZ area under the curve.could have been identiﬁed through arthroscopy, might have
made the differences between early cartilage lesions and
control more obvious.
Of the nine candidate biomarker genes we identiﬁed, three
genes have previously been linked to OA cartilage biology:
TNFAIP6 (TSG-6), IL13RA1, and EGR129e31. The ﬁrst
biomarker TNFAIP6 was shown to be chondroprotective
in an antigen-induced model of arthritis29. Moreover, in
a recent study reported by Adarichev et al.32, TNFAIP6 was
one of the genes most signiﬁcantly altered in their arthritis
gene signature of pre-inﬂamed joints. This gene was also
found to be up-regulated in OA cartilage in the above studies
and in studies fromour laboratory29,32,33. In our current study,
Table V
Summary of AD1f2, blind test and AD1k results. TPFZ correctly
diagnosed disease samples/total diseased samples; TNFZ cor-
rectly diagnosed control samples/total control samples
Parameter AD1f2 Blind AD1k
leave-one-out
cross validation
Number of samples 78 67 145
Number of equations 68* 68* 1y
Sensitivity (TPF) 86% (36/42) 72% (23/32) 76% (56/74)
Speciﬁcity (TNF) 83% (30/36) 66% (23/35) 78% (55/71)
Overall accuracy 85% (66/78) 69% (46/67) 77% (111/145)
*ROC areaO 0.90 against reference data set AD1f2.
yEquation used: XZ17.95 0.28*DCt(G2AN)C 0.93*DCt
(HSPCA)C 1.12*DCt(IL13RA1)C 0.44*DCt(LAMC1) 0.71*DCt
(MAFB)C 0.81*DCt(PF4)C 0.35*DCt(TNFAIP6).however, TNFAIP6 expression was down-regulated in our
early OA blood samples. Nelson et al.34 reported a similar
phenomenon in their study of type II collagen synthesis in
which type II procollagen was increased in OA cartilage but
decreased in OA serum. The down-regulation of TNFAIP6 in
OAblood as observed in our study probably reﬂects systemic
rather than local changes. The second of our biomarker
candidates, IL13RA1, is one of the functional receptor
components of IL13 in blood monocytes35, and is critical for
IL13 expression in response to inﬂammation. IL13 has been
suspected of being protective against cartilage dysfunc-
tion36,37. EGR1, our third biomarker, is a transcriptional
repressor of collagen type II promoter activity. EGR1 was
reported to be down-regulated in human OA cartilage31,38.
Interestingly, our data show that EGR1 expression was also
down-regulated in OA blood.
Other candidate biomarkers, notably PF4, LAMC1 and
HSPCA, have been previously implicated in chondrocyte
disease and other joint diseases, such as rheumatoid
arthritis39e41. Boehm and Fortier42 recently showed that
heat shock protein 90 (hsp90) protein levels were de-
creased in equine OA chondrocytes and that treatment with
hsp90 inhibitor blocked IL-1 induced matrix metalloprotei-
nase (MMP)-13 up-regulation, a key cartilage degrading
enzyme. Interestingly, in our study, HSPCA correlated
signiﬁcantly with OA score (Table IV), a correlation that
indicates that this gene might have a role in OA
pathogenesis. Another interesting ﬁnding from our study is
that LAMC1 was signiﬁcantly correlated with BMI, a risk
factor for OA. Further study is needed to evaluate the roles
of these biomarkers in OA.
869Osteoarthritis and Cartilage Vol. 13, No. 10It is not surprising that we have identiﬁed several
biomarkers that appear to be novel candidates in the
pathogenesis of OA, including G2AN, IKBKAP, and MAFB.
Our ﬁnding that some OA genes have not been identiﬁed in
previous studies, in part reﬂects the fact that there is much
to learn about OA. In our earlier study of cartilage ESTs
study, we identiﬁed 15,000e20,000 cartilage expressed
genes and observed O60% of them had either no known
function in cartilage or no known function at all15e17,33.The
gene expression changes observed in OA blood samples
could also reﬂect systemic change or down-stream re-
sponse of the disease. Functional studies are required to
further clarify the role of these genes in OA.
This study is unique in that we used combinations of
blood RNA biomarkers to diagnose early OA. Biomarker
combinations give higher levels of discrimination than can
be obtained with single biomarkers. The diagnostic capa-
bility of any of the nine biomarkers, individually, ranges from
0.52 to 0.82 in ROC area, whereas the combination of some
of the nine biomarkers has an ROC area over 0.90, a much
higher diagnostic capability.
The discrepancy between the overall classiﬁcation
accuracy for reference data set AD1f2 (85%) and for the
blind sample set (69%) (Table V) is not surprising. This
phenomenon is known as the ‘‘small sample bias’’
effect43,44; that is the reference set is not large enough to
capture all the variance in the population from which the
blind samples have been drawn. If a larger and more varied
set of samples had been used to construct the reference
set, then the blind test accuracy could be expected to
improve. This hypothesis is partially supported by the
results of the ‘‘leave-one-out’’ cross validation (AD1k,
overall accuracy 77%, Table V).
Our best biomarker combinations for mild OA detection
(Fig. 3) compare favorably in diagnostic accuracy to
published diagnostic tests for other types of arthritis. For
example, Uhl et al.45 diagnosed juvenile idiopathic
arthritis of the knee using magnetic resonance imaging
(a diagnostic ‘‘gold standard’’) and a combination of
imaging criteria as graded by ﬁve independent radiolog-
ists and obtained ROC areas of w0.93. Also, Bizzaro
et al.46 evaluated a commercial Enzyme-linked Immuno-
sorbent Assay (ELISA) kit for detecting anti-CCP (cyclic
citrullinated peptide) antibodies for the diagnosis of
rheumatoid arthritis; based on 98 patients with rheumatoid
arthritis and 232 controls found an ROC area of
0.71G 0.07. Thus, using our reference data set, based
on our real-time RT-PCR assay of blood-derived RNA, we
were able to discriminate early OA from control samples
within the range of performance deﬁned by other
diagnostic tests for arthritis.
Furthermore, of the 85 mild OA patients who participated
in our study, 50 of them had had, prior to arthroscopy,
a knee X-ray with a KL score (supplement Table 1). Of
these 50 patients, 76% (nZ 38 with KL ‘‘0’’) based on their
X-ray results alone, would be misdiagnosed as ‘‘normal’’.
Since a KL score of ‘‘1’’ indicates doubtful osteophytes,
another 20% (nZ 10 with KL ‘‘1’’) of our patient set would
also have been radiologically as ‘‘probably normal’’. Thus,
the KL grading system would have misdiagnosed as
‘‘normal’’ as many as to 96% of the patients with early
knee OA. In other words, the KL grading system would have
identiﬁed only 4% (nZ 2, KL ‘‘2’’), or up to 24%
(4%C 20%), of the true positive (with mild OA) patients.
This indicates that KL scores are much less sensitive for
detecting early cartilage lesions than the arthroscopic
grading system, which is in concordance with the reportfrom Brandt et al.47, and further emphasizes the need for
the development of a non-invasive and sensitive early
cartilage lesions diagnostic tool.
Our test for mild knee OA offers a sensitivity of 72e86%
(Table V) and represents a signiﬁcant improvement over
currently available diagnostic tools. Considering that pa-
tients with mild OA are often asymptomatic for years before
developing clinical disease, our test has utility for early
diagnosis and therapeutic intervention for a signiﬁcant
number of patients.
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